Zika Vaccine Race Spurred By Crisis and Profit Potential
The race to find protection against the Zika virus is fueled by something often missing from tropical disease research: the potential for big profit. The prospect of a blockbuster vaccine against a mosquito-borne virus has accelerated the pace of development and attracted the interest of big drugmakers, including Sanofi SA (SASY. PA), GlaxoSmithKline Plc (GSK.L) … Read more